Kezar Life Sciences (NASDAQ: KZR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.260 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kezar Life Sciences (NASDAQ: KZR) through any online brokerage.
Other companies in Kezar Life Sciences’s space includes: Humacyte (NASDAQ:HUMA), Tango Therapeutics (NASDAQ:TNGX), Anika Therapeutics (NASDAQ:ANIK), Talaris Therapeutics (NASDAQ:TALS) and Dyne Therapeutics (NASDAQ:DYN).
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by Wells Fargo on Friday, May 13, 2022. The analyst firm set a price target for 13.00 expecting KZR to rise to within 12 months (a possible 115.23% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Kezar Life Sciences (NASDAQ: KZR) is $6.04 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Kezar Life Sciences.
Kezar Life Sciences’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Kezar Life Sciences.
Kezar Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.